AI assistant
Moleculin Biotech, Inc. — Capital/Financing Update 2016
Apr 28, 2016
34881_rns_2016-04-28_98ef23d0-9cf4-4145-94e4-b0a337961f9f.zip
Capital/Financing Update
Open in viewerOpens in your device viewer
CORRESP 1 filename1.htm
Moleculin Biotech, Inc.
2575 West Bellfort
Suite 333
Houston, TX 77054
April 28, 2016
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Scot Foley
| RE: |
|---|
| Registration Statement on Form S-1 (No. 333-209323) (“Registration Statement”) |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Act”), Moleculin Biotech, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective on May 2, 2016 at 4:30 p.m. Eastern Time, or as soon thereafter as practicable. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
In connection with the foregoing, the Company acknowledges that:
· should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Once the Registration Statement is effective, please orally confirm the event with our counsel Schiff Hardin LLP by calling Cavas Pavri at (202) 724-6847.
Very truly yours,
Moleculin Biotech, Inc.
/s/ Walter Klemp
Walter Klemp
Acting Chief Executive Officer
Field: Page; Sequence: 1; Options: Last
Field: /Page